Artiva Biotherapeutics (ARTV) vs Compugen (CGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Compugen (CGEN) over the past year, gaining 20.8% versus a gain of 20.3%. Artiva Biotherapeutics is the larger company by market cap ($186.9 million vs $174.3 million), about 1.1 times the size, while Compugen is growing revenue faster (+161.1% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | CGEN |
|---|---|---|
| Share price | $3.78 | $1.84 |
| Market cap | $186.85M | $174.29M |
| 1-day change | -1.31% | -2.13% |
| YTD return | -11.89% | +20.26% |
| 1-year return | +20.77% | +20.26% |
| 5-year return | — | -59.47% |
| P/E ratio (TTM) | — | 4.72 |
| EPS (TTM) | $-2.85 | $0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $72.76M |
| Revenue growth (YoY) | -100.00% | +161.14% |
| Net income (latest FY) | $-83.86M | $35.34M |
| Gross margin | — | 87.29% |
| Operating margin | — | 43.05% |
| Net margin | — | 48.57% |
| 52-week high | $14.53 | $3.24 |
| 52-week low | $2.96 | $1.43 |
| Distance from 52-week high | -73.98% | -43.21% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +448.94% | +160.87% |
| Average volume | 792.26K | 223.56K |
| Shares outstanding | 49.43M | 94.72M |
| Employees | 134 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Compugen grew revenue faster in its latest fiscal year (+161.14% vs -100.00%).
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees
ARTV vs CGEN FAQ
Which is bigger, Artiva Biotherapeutics or Compugen?
Artiva Biotherapeutics (ARTV) is larger, with a market capitalization of $186.85M compared with $174.29M for Compugen (CGEN).
Which stock has performed better over the past year, ARTV or CGEN?
ARTV returned +20.77% over the past 12 months, compared with +20.26% for CGEN (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Compugen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.